Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Drug-coated balloons comparable to drug-eluting stents when PCI patients have a high bleeding risk

Drug-coated balloons were associated with a lower risk of bleeding after PCI than drug-eluting stents, the study's authors reported. 

VIDEO: TAVR durability outperforms surgical valves

Michael J. Reardon, MD, professor of cardiothoracic surgery and Allison Family Distinguished chair of cardiovascular research at Houston Methodist DeBakey Heart and Vascular Center, presented pooled data at ACC.22 from the CoreValve SURTAVI trials that found transcatheter aortic valve replacement (TAVR) was more durable than surgical aortic valve replacement (SAVR) devices.

Nurses caring for a COVID-19 patient in the COVID unit at Banner University Medical Center in Phoenix.

An updated look at what cardiologists know about heart damage among COVID-19 patients

An international analysis published in Circulation and a new scientific statement from the American Heart Association both explore the latest data on heart complications associated with COVID-19. 

Fitbit’s latest AFib algorithm receives FDA clearance, will be available ‘soon’

The new algorithm was designed to evaluate a user's heart rhythm while they are still or even sleeping. 

How the continued rise of TAVR has impacted SAVR outcomes

Did SAVR outcomes suffer due to the rapid rise of TAVR? A team of researchers aimed to find out with a brand new analysis. 

Adam Greenbaum, MD, Emory, explains the CLASP TR trial of the Pascal clip device for transcatheter repair, which was a late-breaking ACC22 study.

VIDEO: Pascal effective in transcatheter repair of tricuspid valve regurgitation

Adam Greenbaum, MD, co-director of the Structural Heart and Valve Center at Emory University Hospital Midtown in Atlanta, explains details from the late-breaking CLASP TR trial at ACC.22.

Several ACC 2022 late-breaking trials may have impacts on clinical practice for interventional cardiology and structural heart. One trial compared FFR vs. IVUS guided PCI for intermediate coronary lesions. Photos by Dave Fornell

Key interventional cardiology takeaways from ACC.22

Several late-breaking clinical trials at ACC.22 will likely impact clinical practice. Below are summaries of a few key trials and their takeaways for interventional cardiology and structural heart interventions. 

An implantable cardioverter defibrillator (ICD) and its associated leads viewed on a X-ray. Old leads are often abandon in veins and new ones added, but a new study of 1 million patients at ACC22 showed there is higher mortality if a device becomes infected and the leads are left behind. Image from RSNA.

VIDEO: Lowering mortality rates from infected EP implantable cardiac devices

Sean Pokorney, MD, director of the arrhythmia core lab, Duke Clinical Research Institute, assistant professor of Medicine, Duke University, discusses a late-breaking ACC 2022 study that shows mortality is higher in patients with implantable electrophysiology (EP) device infections where the leads are not explanted.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.